市場調査レポート

商品コード

1447789

前立腺がん治療の世界市場規模、シェア、成長分析、薬剤別、流通チャネル別-産業予測、2024～2031年

Global Prostate Cancer Treatment Market Size, Share, Growth Analysis, By Drug(Extruded Chemotherapy, Biological Therapy), By Distribution Channel(Hospitals Pharmacies, Drug Stores & Retail Pharmacies) - Industry Forecast 2024-2031

出版日: 2024年02月27日 | 発行: SkyQuest

| ページ情報: 英文 157 Pages | 納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 830,510円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 971,540円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,112,570円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.70円

全表示
概要
目次

概要

サンプル依頼リストに入れる

前立腺がん治療の世界市場規模は2022年に120億米ドルと評価され、2023年の130億4,000万米ドルから2031年には254億2,000万米ドルに成長し、予測期間（2024～2031年）のCAGRは8.70％で成長する展望です。

前立腺がん治療の世界市場は、世界で最も一般的に診断されるがんの一つである前立腺がんの有病率に牽引され、極めて重要な市場洞察を伴うダイナミックな状況を呈しています。同市場の主要目的は、前立腺がんに罹患している人々に先進的かつ効果的な治療オプションを提供することにあります。高齢化、意識の高まり、新しい治療法や薬剤の開発につながる早期診断への取り組みなど、さまざまな要因が市場の成長を後押ししています。とはいえ、市場には治療費の高騰や前立腺がん治療に伴う潜在的な副作用などの制約があり、これが普及の妨げになる可能性もあります。主要促進要因としては、人口動態の高齢化、前立腺がんの罹患率の上昇、医薬品介入の急増、治療選択肢に関する意識の高まり、研究開発資金の増加、市場浸透の強化、革新的な治療法の利用可能性とともに洗練されたパイプライン医薬品の出現などが挙げられます。さらに、前立腺がん治療に対する需要の高まりと、非転移性去勢抵抗性前立腺がんと転移性ホルモン非依存性前立腺がんシナリオにおけるホルモン療法の利用が、市場拡大に寄与しています。さらに、新興経済諸国は未開拓の可能性を秘めており、予測期間中に有利な成長機会を提供します。しかし、未開発地域における回復期間の長期化や前立腺がん治療に対する需要の低迷は、市場の成長を阻害する可能性があります。世界の前立腺がん治療市場における課題には、より個別化された治療アプローチの必要性や規制の枠組みの進化などがあります。それにもかかわらず、この市場には、市場が進化し続けるにつれて個々の患者の治療精度を大幅に高める薬剤ターゲティングの強化を通じて、大きなビジネス機会が存在します。研究開発への投資が増加すれば、より効果的な治療法が開発され、前立腺がん患者のQOLと生存率が向上する可能性があります。

技術分析
価格分析
サプライチェーン分析
バリューチェーン分析
市場のエコシステム
IP分析
貿易分析
スタートアップ分析
原材料の分析
イノベーションマトリクス
パイプライン製品の分析
マクロ経済指標
主要投資の分析
主要成功要因
競合の程度

市場力学と展望

市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
規制情勢
ポーターの分析
将来の混乱についての特別な考察

前立腺がん治療の世界市場：薬剤別

市場概要
化学療法
生物学的療法
ホルモン療法
その他

前立腺がん治療の世界市場：流通チャネル別

市場概要
病院薬局
ドラッグストアと小売薬局
オンライン薬局

前立腺がん治療の世界市場規模：地域別

市場概要
北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- その他の欧州地域
アジア太平洋
- 中国
- インド
- 日本
- 韓国
- その他のアジア太平洋
ラテンアメリカ
- ブラジル
- その他のラテンアメリカ地域
中東・アフリカ
- GCC諸国
- 南アフリカ
- その他中東・アフリカ地域

競合情勢

上位5社の比較
主要企業の市場ポジショニング（2021年）
主要市場企業が採用した戦略
主要成功戦略
市場における最近の活動
主要企業の市場シェア（2021年）

主要企業プロファイル

Ferring Pharmaceuticals Inc.（スイス）
GlaxoSmithKline Plc.（英国）
Ipsen Pharma（フランス）
AstraZeneca plc（英国）
F. Hoffmann-La Roche AG（スイス）
Astellas Pharma Inc（日本）
Johnson & Johnson（米国）
Bayer AG.（ドイツ）
Bristol-Myers Squibb Company（米国）
Takeda Pharmaceutical Company Ltd（日本）
Amgen Inc.（米国）
Pfizer Inc（米国）
Novartis AG（スイス）
Sanofi（フランス）
Merck & Co., Inc（米国）
Eli Lilly and Company（米国）
Gilead Sciences, Inc（米国）
AbbVie Inc（米国）
Celgene Corporation（米国）
Teva Pharmaceutical Industries Ltd（イスラエル）

Product Code: SQMIG35I2244

Global Prostate Cancer Treatment Market size was valued at USD 12 billion in 2022 and is poised to grow from USD 13.04 billion in 2023 to USD 25.42 billion by 2031, growing at a CAGR of 8.70% in the forecast period (2024-2031).

The global market for prostate cancer treatment presents a dynamic landscape accompanied by crucial market insights, driven primarily by the prevalence of prostate cancer, one of the most commonly diagnosed cancers in men worldwide. The market's main objective revolves around offering advanced and efficacious treatment options for individuals afflicted with this condition. Various factors fuel market growth, including the aging population, heightened awareness, and early diagnosis efforts leading to the development of novel treatments and medications. Nevertheless, the market encounters constraints such as elevated treatment expenses and potential side effects associated with prostate cancer therapies, which could impede widespread adoption. Key drivers encompass the aging demographic, escalating incidence rates of prostate cancer, proliferation of pharmaceutical interventions, heightened awareness regarding treatment options, increased research and development funding, enhanced market penetration, and the emergence of sophisticated pipeline drugs alongside the availability of innovative therapies. Additionally, the rising demand for prostate cancer treatments and the utilization of hormonal therapy in non-metastatic castration-resistant and metastatic hormone-naive prostate cancer scenarios contribute to market expansion. Furthermore, developing economies present untapped potentials, offering lucrative growth opportunities during the forecast period; however, prolonged recovery periods in underdeveloped regions and subdued demand for prostate cancer drugs may hinder market growth. Challenges in the global prostate cancer treatment market include the necessity for a more tailored treatment approach and evolving regulatory frameworks. Nonetheless, substantial opportunities exist in this market through drug targeting enhancements, which significantly augment treatment precision for individual patients as the market continues to evolve. Increased investment in research and development endeavors could lead to the development of more effective therapies, thereby enhancing the quality of life and survival rates for prostate cancer patients.

Top-down and bottom-up approaches were used to estimate and validate the size of the Prostate Cancer Treatment Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Prostate Cancer Treatment Market Segmental Analysis

The global prostate cancer treatment market is segmented on the basis of drug, distribution channel, and region. By drug, the market is segmented into chemotherapy, biological therapy, hormone therapy, and others. By distribution channel, the market is segmented into hospitals pharmacies, drug stores & retail pharmacies, and online pharmacies. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Prostate Cancer Treatment Market

The rising prevalence of prostate cancer is driven by various factors, including an aging global population and improved diagnostic techniques, leading to increased awareness and earlier detection. As the incidence of prostate cancer is expected to rise, particularly among older men, there is a growing demand for effective treatment options in the global market.

Restraints in the Prostate Cancer Treatment Market

the market faces challenges such as high costs associated with targeted therapies and immunotherapies, which can pose affordability issues for patients and healthcare providers alike. Despite the promise of these advanced therapies in improving patient outcomes, access remains limited due to financial constraints. Addressing cost barriers is crucial to ensure widespread access to potentially life-saving treatments for prostate cancer.

Market Trends of the Prostate Cancer Treatment Market

A notable trend in the market is the adoption of personalized medicine approaches in prostate cancer treatment, which involves tailoring treatments based on individual genetic and molecular characteristics. This approach enhances treatment accuracy and reduces the risk of unnecessary interventions, thereby minimizing side effects and improving overall outcomes. Popular biochemical tests such as the Prostate Health Index (PHI), Oncotype DX Genomic Prostate Score, and Prolaris test are utilized to identify genetic variations in cancer cells, guiding treatment decisions. Targeted therapies like olaparib and rucaparib, which specifically target tumors with DNA repair process alterations, exemplify this personalized approach and demonstrate potential in treating advanced prostate cancer.

Executive Summary

Market Overview
Wheel of Fortune

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Parent Market Analysis

Market Overview
Market Size
Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges

Key Market Insights

Technology Analysis
Pricing Analysis
Supply Chain Analysis
Value Chain Analysis
Ecosystem of the Market
IP Analysis
Trade Analysis
Startup Analysis
Raw Material Analysis
Innovation Matrix
Pipeline Product Analysis
Macroeconomic Indicators
Top Investment Analysis
Key Success Factor
Degree of Competition

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Regulatory Landscape
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact

Global Prostate Cancer Treatment Market by Drug

Market Overview
Extruded Chemotherapy
Biological Therapy
Hormone Therapy
and Others

Global Prostate Cancer Treatment Market by Distribution Channel

Market Overview
Hospitals Pharmacies
Drug Stores & Retail Pharmacies
and Online Pharmacies

Global Prostate Cancer Treatment Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2021
Strategies Adopted by Key Market Players
Top Winning Strategies
- By Development
- By Company
- By Year
Recent Activities in the Market
Key Companies Market Share (%), 2021

Key Company Profiles

Ferring Pharmaceuticals Inc. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline Plc. (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ipsen Pharma (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Astellas Pharma Inc (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG. (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Ltd (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences, Inc (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Celgene Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments